Public Company Edition: Several special purpose acquisition corporations have emerged, including various health care- and life science-focused SPACs. Also, Alvotech entered into a $965m refinancing agreement and Avidity grossed $461m in a follow-on offering, among other updates.

Public Company Edition: Verona Pharma arranged up to $400m in new debt and up to $250m in revenue-related financing ahead of its COPD drug launch. Also, Organon, Sobi and Pacira priced $1bn, $275.1m and $250m note sales, respectively. Marinus, Emergent and Ginkgo cut jobs.

The company’s PD-1 inhibitor Jemperli plus GSK's own PARP Zejula has scored a win in a late-stage endometrial cancer trial that could lead to a key label expansion.

Jemperli has struggled to gain a presence in cancer immunotherapy so far, but GSK believes the PD-1 therapy can hold its own against Merck & Co’s mega-blockbuster Keytruda in a few key areas.